These findings suggest a promising therapeutic approach to control immune dysregulation in peri-implantitis through therapeutic inhibition of NF-κB expression in the RANKL/RANK/OPG axis (Figure 5). This evidence concerns the gene TNFSF11 and Peri-Implantitis.